drugset / Trial / NCT02305446

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

NCT02305446

Phase 3 Completed 55 enrolled Novartis
NaSingle-groupOpen-labelPrevention

Summary

The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the Meningococcal Group B Vaccine in other studies.

Timeline

Start
2014-12
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Bexsero Vaccine 0.5 ml Intramuscular